摘要
目的探讨罗沙司他对规律腹膜透析肾性贫血患者脂代谢和血红蛋白达标率的影响。方法选取2020年1月—2021年3月在该院确诊的60例规律腹膜透析肾性贫血患者,采用简单随机分组将患者分为观察组和对照组,每组30例。对照组患者采用静脉注射重组人促红细胞生成素(rhEPO)-β注射液治疗,观察组患者采用口服罗沙司他胶囊治疗,比较两组患者的临床疗效、脂代谢指标[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)和总胆固醇(TC)]、炎症因子[肿瘤坏死因子α(TNF-α)和白介素6(IL-6)、超敏C反应蛋白(hs-CRP)]及不良反应发生率。结果两组患者临床有效率比较差异无统计学意义(P>0.05);治疗后,观察组患者的HDL-C水平(2.51±0.55)mmol/L明显高于对照组,差异有统计学意义(t=7.144,P<0.05),LDL-C(1.18±0.42)mmol/L、TG(1.68±0.28)mmol/L和TC(3.01±1.29)mmol/L水平明显低于对照组,差异有统计学意义(t=11.088、9.058、3.584,P<0.05);观察组患者血清TNF-α、IL-6和hs-CRP水平明显低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论罗沙司他治疗可以明显提高规律腹膜透析肾性贫血患者的临床疗效,改善贫血问题,降低血脂。
Objective To investigate the effects of rosallistat on lipid metabolism and hemoglobin compliance rate in patients with renal anemia on regular peritoneal dialysis.Methods a total of 60 patients with renal anemia on regular peritoneal dialysis who were diagnosed in the hospital from January 2020 to March 2021 were randomly divided into observation group and control group,with 30 patients in each group.The control group was treated with intravenous injection of recombinant human erythropoietin(rhEPO-β) injection,and the observation group was treated with oral rosalista capsule.Clinical efficacy,lipid metabolism indexes [high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),triglyceride(TG) and total cholesterol(TC)],inflammatory factors [tumor necrosis factor-a(TNF-α) and interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP)] and incidence of adverse reactions were compared between the two groups.Results There was no statistically significant difference in the clinical effective rate between the two groups(P>0.05).After treatment,the HDL-C level of observation group(2.51±0.55) mmol/L was significantly higher than that of control group,and the difference was statistically significant(t=7.144,P<0.05).LDL-C(1.18±0.42) mmol/L,TG(1.68±0.28) mmol/L and TC(3.01±1.29) mmol/L were significantly lower than those in the control group,and the difference was statistically significant(t=11.088,9.058,3.584,P<0.05).The levels of TNF-α,IL-6 and hs-CRP in observation group were significantly lower than those in control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Rosallistat treatment can significantly improve the clinical effect of regular peritoneal dialysis patients with renal anemia,improve anemia,reduce blood lipids,improve the rate of hemoglobin up to standard.
作者
张策
王军升
李也
ZHANG Ce;WANG Junsheng;LI Ye(Department of Nephrology,Suqian Hospital Affiliated to Xuzhou Medical University(Suqian People's Hospital,Nanjing Gulou Hospital Group),Suqian,Jiangsu Province,223800 China;Department of Anesthesiology,Suqian Hospital Affiliated to Xuzhou Medical University(Suqian People's Hospital,Nanjing Gulou Hospital Group),Suqian,Jiangsu Province,223800 China)
出处
《世界复合医学》
2021年第12期183-186,共4页
World Journal of Complex Medicine
关键词
罗沙司他
腹膜透析
肾性贫血
脂代谢
Rosalastat
Peritoneal dialysis
Renal anemia
Lipid metabolism
